Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Viral hepatitis is on the rise. Tackling hepatitis B in Africa is key to fighting back. “HIV has been an acute pandemic with resources thrown at it.

That’s a completely different picture than hep B, which has travelled with humankind for tens of thousands of years - and by dint of that invisible carriage, has never had that injection of political advocacy, funding, energy and education that’s gone into HIV,” says Philippa Matthews, an immunologist at the University of Oxford, UK, who studies viral infections such as HBV.

Read More

Similar stories

Immune response may be harnessed to control HIV

Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.

Oxford and GSK launch £50m programme to advance cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Fitness compensation in m.tuberculosis: a game of genetic chess

Viktoria Brunner takes us behind the scenes of their latest publication 'Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis' published in Microbial Genomics.

Emerging Leaders Prize recognises future leaders in hepatitis research

Three outstanding hepatitis researchers have been announced today as winners of the Medical Research Foundation’s seventh Emerging Leaders Prize.